News
Immunetune Announces Presentations at Industry Conferences during April and May 2022
Immunetune Announces Presentations at Industry Conferences during April and May 2022 LEIDEN, the Netherlands, April 20, 2022 -- Immunetune, a preclinical-stage biotech developing next-generation DNA vaccines against cancer and infectious diseases, today announced the...
Sachs European Life Sciences CEO Forum
Sachs 15th Annual European Life Science CEO Forum February 28 - March 4, Digital Conference
Immunetune Publishes Preclinical Data on Novel Adjuvant in the Journal Vaccine
Immunetune Publishes Preclinical Data on Novel Adjuvant in the Journal Vaccine LEIDEN, the Netherlands, February 23, 2022 -- Immunetune, a preclinical-stage biotech developing next-generation DNA vaccines against cancer and infectious diseases, announced today...
Sachs European Life Sciences CEO Forum
Sachs 15th Annual European Life Science CEO Forum February 28 - March 4, Digital Conference
Immunetune Publishes Preclinical Data on Novel Adjuvant in the Journal Vaccine
Immunetune Publishes Preclinical Data on Novel Adjuvant in the Journal Vaccine LEIDEN, the Netherlands, February 23, 2022 -- Immunetune, a preclinical-stage biotech developing next-generation DNA vaccines against cancer and infectious diseases, announced today...
Immunetune Establishes International Scientific Advisory Board
Immunetune Establishes International Scientific Advisory Board LEIDEN, the Netherlands, January 11, 2022 -- Immunetune, a preclinical-stage biotech developing next-generation DNA vaccines against cancer and infectious diseases, today announced the appointment of...
Immunetune Announces Presentations at Industry Conferences during November 2021
Immunetune Announces Presentations at Industry Conferences during November 2021 LEIDEN, the Netherlands, November 2, 2021 -- Immunetune, a preclinical-stage biotech developing next-generation DNA vaccines against cancer and infectious diseases, today announced...